Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Neuropharmacology. 2015 Mar 4;95:121–129. doi: 10.1016/j.neuropharm.2015.02.023

Fig. 3.

Fig. 3

Effect of VU0364770 (100 mg/kg, po) and LSP1-2111 (15 mg/kg, i.p.) on established l-DOPA-induced dyskinesia. Two different sets of l-DOPA-treated dyskinetic rats were acutely challenged with VU0364770 (A, n = 11) or LSP1-2111(B, n = 15) and their AIM scores were rated. None of the compounds had any effect on the peak severity of established dyskinesias but VU0364770 prolonged the duration of the AIMs (grey diamonds in A). p < 0.05, * vs. l-DOPA + vehicle, two-way RM ANOVA and post hoc Bonferroni test.